enlicitide decanoate (mk-0616 oral pcsk9 inhibitor) cardiovascular outcomes study (mk-0616-015) coralreef outcomes

Conditions: Arteriosclerosis; Hypercholesterolaemia

Summary: this is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor, in participants with high cardiovascular risk. the primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (mace) including coronary heart disease (chd) death, ischemic stroke, myocardial infarction (mi), acute limb ischemia or major amputation, or urgent arterial revascularization.


Eligibility criteria:
inclusion criteria: * meets one of the following: 1. age ≥18 years with a history of a major atherosclerotic cardiovascular disease (ascvd) event defined as at least 1 of the following: ≥30 days post mi (presumed type 1 due to plaque rupture or erosion); ≥30 days post ischemic stroke (presumed due to atherosclerosis); or ≥30 days post successful peripheral (carotid or lower extremity) arterial revascularization (surgical or endovascular) or major (ankle or above) amputation due to atherosclerosis; or 2. high risk for first major ascvd event defined as at least 1 of the following: age ≥50 years with evidence of coronary artery disease; age ≥50 years with evidence of atherosclerotic cerebrovascular disease; age ≥50 years with evidence of peripheral arterial disease; or age ≥60 years with diabetes mellitus and at least one of the following: microvascular disease or urine albumin-creatinine ratio ≥30 mg/mmol within 6 months before visit 1, daily insulin use, or diabetes for ≥10 years * has fasted lipid values (evaluated by the central laboratory) at visit 1 (screening) as follows: 1. history of major ascvd event: ldl-c ≥70 mg/dl (1.81 mmol/l) or non-hdl-c ≥100 mg/dl (2.59 mmol/l) 2. high risk for first major ascvd event: ldl-c ≥90 mg/dl (2.33 mmol/l) or non-hdl-c ≥120 mg/dl (3.11 mmol/l) * is treated with moderate- or high-intensity statin (± nonstatin lipid-lowering therapy \[llt\]) at visit 1 * is on a stable dose of all background llts (including statin and nonstatin agents) for at least 30 days before visit 1 (screening) with no medication or dose changes planned during the participation in the study exclusion criteria: * has a history of homozygous familial hypercholesterolemia (fh) based on genetic or clinical criteria, compound heterozygous fh, or double heterozygous fh * has new york heart association class iv heart failure, last known left ventricular ejection fraction ≤25% by any imaging method, or had a heart failure hospitalization within 3 months before visit 1 (screening) * has recurrent ventricular tachycardia within 3 months prior to randomization * has a planned arterial revascularization procedure * is undergoing or previously underwent an ldl-c apheresis program within 3 months before visit 1 (screening) or plans to initiate an ldl-c apheresis program * was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (pcsk9) inhibitors without adequate washout. * has a fasting triglyceride value ≥400 mg/dl (≥4.52 mmol/l) at visit 1 (screening)